Sanofi SNY announced that the European Commission has approved its Bruton's tyrosine kinase (BTK) inhibitor, Cenrifki ...

An experimental MS therapy given as a nasal spray has started dosing its final participant in a Phase 2a trial of people with ...

Sanofi said it received European Union approval for Cenrifki, a new multiple sclerosis medicine, after U.S. regulators ...

The European Commission has approved Sanofi’s Cenrifki (tolebrutinib) for adults with secondary progressive multiple ...

SAN DIEGO -- Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive multiple sclerosis (SPMS), the phase III HERCULES trial showed. The Bruton's ...

Sanofi’s Cenrifki (tolebrutinib) approved in the EU as the first disability-targeting medicine for secondary progressive multiple sclerosis ...

New research led by a St. Michael's Hospital clinician-scientist and published in the New England Journal of Medicine suggests that a therapy called Tolebrutinib could reduce disability progression in ...

Living with a chronic, progressive condition such as secondary progressive multiple sclerosis (SPMS) can affect both your physical and mental health. SPMS results in a gradual decline in function over ...

The HERCULES study of tolebrutinib is the first and only to show reduced confirmed disability progression at 6 months in nonrelapsing secondary progressive multiple sclerosis (MS). The HERCULES ...

A Cleveland Clinic-led clinical trial of tolebrutinib, an investigational oral Bruton's tyrosine kinase inhibitor, a group of drugs originally developed to treat lymphomas and related blood disorders, ...

Please provide your email address to receive an email when new articles are posted on . Tolebrutinib was associated with a 31% reduced risk for 6-month confirmed disability progression vs. placebo.

The number of cortical lesions at baseline may indicate a patient's risk of developing secondary progressive multiple sclerosis (MS), according to new research. Cortical lesions also may be an early ...